Background: Clostridium difficile-associated diarrhoea (CDAD) is an increasingly common and life threatening consequence of modern medical practice. Recurrent disease is seen in up to one-third of patients and there is no consensus on optimal therapy. Restoration of normal colonic flora addresses the underlying pathogenic mechanism in CDAD. Methods: We describe the use of nasogastrically administered faecal transplant in the treatment of 15 patients with recurrent CDAD. Retrospective case note review was used to review the success and safety of therapy.
Introduction
Clostridium difficile-associated diarrhoea (CDAD) is a common and potentially severe healthcare associated infection. During recent outbreaks, mortality is described as high as 33% 1 and relapse, defined as the return of diarrhoea after complete resolution, is observed in up to 28%. 1 Relapse is seen more frequently in individuals over the age of 65 years and requiring prolonged hospital stays 2 and subsequent relapses occur in up to 50-65%. 3 In recent years, a change in the epidemiology of CDAD has been seen with an increase in the incidence, more severe disease and higher relapse rates. 4 There is little good evidence to delineate the optimal management of multiple relapses. Strategies such as pulsed/tapered antibiotics, 3 the administration of probiotics 5 and intravenous immunoglobulin 6 have been used with varying success.
Since depletion of the normal gastrointestinal tract flora is the basis of the pathogenesis of CDAD, 7 repopulation of the normal flora postulates an attractive therapeutic intervention. As it is unclear which organism(s) are protective against C. difficile disease, faecal therapy could be an effective strategy to replace the bowel micro-flora in patients with recurrent CDAD. The administration of donor stool by retention enemas or colonoscopy is well described. 8, 9 However, administration via a nasogastric tube to patients with recurrent CDAD has been reported, predominantly, in the outpatient setting. 10 Nasogastric administration is technically easier to perform and provides more extensive exposure of the gastrointestinal tract to donor flora. Herein, we present our clinical experience with this therapy in 15 individual patients with severe recurrent CDAD in the Glasgow Infection Unit.
Methods

Patients
Faecal transplantation has been offered as a therapeutic intervention to patients with relapsed CDAD, who were able to give informed consent, since September 2003. Relapsed CDAD was defined as recurrence of loose stool, following successful antibiotic treatment, in a patient recently treated for toxin positive CDAD. Relapse typically happened within 7 days of stopping metronidazole or vancomycin. These patients relapsed despite receiving at least one 10-day course each of metronidazole and vancomycin.
Stool transplantation procedure
Stool transplant procedure broadly followed that previously described. 10 All patients gave informed consent for the procedure. Healthy related volunteers, identified as potential donors, were screened for blood borne viruses, syphilis and enteropathogens 10 prior to stool donation. Donor recipients were treated with oral vancomycin (125 mg, four times daily) prior to faecal transplant which was discontinued 12 h before the procedure. Prior to the transplant, donor recipients received proton pump inhibition (omeprazole 20 mg) to produce a favourable gastric pH. Thirty grams of fresh donor stool was obtained, blended in a household blender with 150 ml 0.9% saline and filtered to produce a preparation of faecal fluid. Thirty millilitres of faecal fluid was administered via a nasogastric tube. The tube was removed immediately post procedure. Patients were observed overnight and discharged home the following day where possible.
Data collection and ethics
A retrospective case note review was undertaken to assess efficacy and safety of this technique. The use of this technique was discussed with the local ethics committee. In these patients, faecal transplantation was used as a published treatment and this report constitutes a review of our clinical practice. As this does not represent research, research ethics approval was not required.
Results
Patient characteristics
Fifteen patients were offered, accepted and received transplantation ( Table 1) . Eleven were inpatients at the time of the transplant and four were readmitted following recent discharge. All but one patient were female with a median age of 81.5 years (range 68-95 years). There was a median of 4 (range 3-7) previous episodes of CDAD. All had previously received numerous courses of antibiotics for recurrent CDAD. Patients 13, 14 and 15 had recurrent disease despite a prolonged pulsed/tapered course of vancomycin and immunoglobulin therapy ( Table 1) . Patients had significant co-morbidity with a high proportion demonstrating hypoalbuminaemia, high white cell response and renal dysfunction during episodes.
Outcomes
Following transplantation, 10 patients were discharged home the following day and 5 remained in hospital for ongoing general medical and nursing care. Eleven patients were symptom free at followup (median 16 weeks after treatment, range 4-24 weeks). Patient 3 relapsed 29 days after stool transplant, having received broad-spectrum antibiotics for presumed aspiration pneumonia following upper gastrointestinal haemorrhage. Patients 2 and 7 failed to respond to stool transplant with recurrence of loose stool and received a further 10-day course of oral metronidazole. They were symptom free at 8-and 24-month follow-up, respectively. Patient 11 required a second transplant because of relapse after receiving an inadequate initial donor stool sample. This patient was diarrhoea free 12 weeks after this. There were no adverse effects related to the transplantation in any patient.
Discussion
Of our 15 patients, faecal transplantation cured 11 (73%), whilst four relapsed. Two of these responded to a further 10-day course of metronidazole, whereas numerous antibiotic courses had previously failed. This has been described previously 10 and presumably, faecal transplant replaces sufficient gut flora to allow successful antibiotic treatment. One patient relapsed after receiving a low-volume faecal transplant. This lady was then cured following a second transplant using the correct amount of donor stool. This highlights the need to give sufficient donor stool to provide appropriate amounts of flora. One patient relapsed after receiving broadspectrum antibiotics. Having been C. difficile toxin and culture positive 6 days prior to faecal transplant, this patient became C. difficile toxin and culture negative, 12 and 16 days after transplant. This demonstrates the frailty of the gut flora and underlines the continued need to limit the use of broadspectrum antibiotics in such patients. As older people, combining significant comorbidity and recurrent CDAD, our cohort was typical of the patients seen in current clinical practice. In the initial description of this technique, the majority (72%) of patients were treated as outpatients. 10 Our patients were more dependent upon inpatient hospital care and despite this the success rate was similar to that previously described for this technique. Furthermore, our patients were pretreated with lower doses of oral vancomycin for longer. Data does not confirm that higher doses of vancomycin are more successful at curing CDAD. 11 The longer duration of vancomycin used prior to transplant resulted from the time taken to screen donors and arrange stool administration. As each patient had previously suffered clinical relapse upon cessation of antibiotics, there was reluctance to stop vancomycin until the transplant could be undertaken. Since each of these patients had failed previous courses of vancomycin and since relapse is often associated with reactivation of, or reinfection with, antibiotic-resistant spores, 7 it is unlikely that this influenced the results. However, in the absence of a control group this remains a possibility.
We used the absence of loose stool as a sign of cure. Not all patients had C. difficile toxin analysis at follow-up. It is recognized that stool toxin assays can remain positive for several weeks after successful treatment of CDAD 11 and these assays are not used as a 'test of cure' in clinical practice.
There is an absence of high-level evidence in the management of recurrent CDAD. Our use of this technique in a typical patient group, has added to the accumulated observational data that this technique is effective. There is medical concern about causing infection in stool recipients as well as concerns about patient acceptance of this treatment. In our population, the administration of donor stool via a nasogastric tube was well tolerated with upper gastrointestinal haemorrhage in one patient being the only adverse event. This lady was taking both aspirin and non-steroidal anti-inflammatory drugs and it is felt that the upper gastrointestinal haemorrhage related to this rather than the faecal transplant, however, this cannot be proven categorically. Despite the aesthetic aspect there was a high level of patient acceptance with one highly satisfied patient feeling compelled to publicize the treatment in the national press. Faecal transplantation has become an established mode of therapy for recurrent CDAD in our unit, usually after failure of pulsed/tapered vancomycin therapy. This approach can be considered for patients who continue with recurrent disease despite other treatment modalities. An appropriately controlled clinical study would better delineate its role in the management of this difficult and debilitating condition.
